Contact
searchSearch
HMP Global
Login

Advertisement

Advertisement

Advertisement

Advertisement

ADVERTISEMENT

RET+ NSCLC Specialty Channel

News
FDA Approves Selpercatinib for Locally Advanced or Metastatic RET Fusion-Positive NSCLC and Solid Tumors
09/22/2022

Derek Cowsert

Derek Cowsert
On September 21, 2022, the FDA granted approval to oral kinase inhibitor, selpercatinib, either 120 mg or 160 mg twice daily based on body weight (less than 50 kg vs more than 50 kg, respectively), for adult patients with locally advanced or...
On September 21, 2022, the FDA granted approval to oral kinase inhibitor, selpercatinib, either 120 mg or 160 mg twice daily based on body weight (less than 50 kg vs more than 50 kg, respectively), for adult patients with locally advanced or...
On September 21, 2022, the FDA...
09/22/2022
Oncology
Quiz
Quiz: Complete Responses With Pralsetinib in Patients With RET-Altered NSCLC on the ARROW Trial
07/25/2022
According to an interim analysis of the multi-cohort, open-label, phase 1/2 ARROW trial, how many patients with RET+ NSCLC a complete response when treated with pralsetinib?
According to an interim analysis of the multi-cohort, open-label, phase 1/2 ARROW trial, how many patients with RET+ NSCLC a complete response when treated with pralsetinib?
According to an interim analysis...
07/25/2022
Oncology
Quiz
Quiz: Selpercatinib Maintains Antitumor Activity in Which Types of RET Fusion-Positive Cancers?
07/19/2022
Findings from the phase 1/2 LIBRETTO-001 trial found that selpercatinib yielded durable antitumor activity in patients with what types of locally advanced and/or metastatic RET fusion-positive solid tumors?
Findings from the phase 1/2 LIBRETTO-001 trial found that selpercatinib yielded durable antitumor activity in patients with what types of locally advanced and/or metastatic RET fusion-positive solid tumors?
Findings from the phase 1/2...
07/19/2022
Oncology
Quiz
Quiz: Selpercatinib vs Other Non-Specific RET Inhibitors for RET-Altered NSCLC and Thyroid Cancer
07/13/2022
On indirect comparison, did study findings presented at the 2022 ASCO Annual Meeting find the safety profile with selpercatinib to be better, worse, or similar compared to previously used non-specific RET-inhibitors in patients with...
On indirect comparison, did study findings presented at the 2022 ASCO Annual Meeting find the safety profile with selpercatinib to be better, worse, or similar compared to previously used non-specific RET-inhibitors in patients with...
On indirect comparison, did...
07/13/2022
Oncology
Conference Coverage
Experts Observe Durable Antitumor Activity With Selpercatinib for RET Fusion-Positive Solid Tumors
06/28/2022

Hina M. Porcelli

Hina M. Porcelli
Selpercatinib continues to demonstrate robust antitumor activity in patients with varying RET fusion-positive solid tumor cancers, according to an update from the LIBRETTO-001 trial presented at the 2022 ASCO Annual Meeting.
Selpercatinib continues to demonstrate robust antitumor activity in patients with varying RET fusion-positive solid tumor cancers, according to an update from the LIBRETTO-001 trial presented at the 2022 ASCO Annual Meeting.
Selpercatinib continues to...
06/28/2022
Oncology
News
Selpercatinib Demonstrates Safety, Efficacy in RET-Altered NSCLC and Thyroid Cancer Regardless of Prior Treatment Status
06/28/2022

Hina M. Porcelli

Hina M. Porcelli
Findings from a systematic review and meta-analysis show that selpercatinib is a safe and effective option for patients with RET-altered NSCLC and thyroid cancer, regardless of previous therapies or RET alteration type.
Findings from a systematic review and meta-analysis show that selpercatinib is a safe and effective option for patients with RET-altered NSCLC and thyroid cancer, regardless of previous therapies or RET alteration type.
Findings from a systematic...
06/28/2022
Oncology
News
European Commission Approves Pralsetinib for Patients with RET+ NSCLC
12/15/2021
The EC has granted conditional marketing authorization to pralsetinib for treatment-naive adult patients with RET-fusion positive NSCLC.
The EC has granted conditional marketing authorization to pralsetinib for treatment-naive adult patients with RET-fusion positive NSCLC.
The EC has granted conditional...
12/15/2021
Oncology
Test Your Knowledge
Quiz: Is RNA-Sequencing Consistent In Detecting RET Fusions in Lung Adenocarcinoma?
11/22/2021
True or false: RNA-sequencing was not consistent with DNA-sequencing in detecting RET fusions.
True or false: RNA-sequencing was not consistent with DNA-sequencing in detecting RET fusions.
True or false: RNA-sequencing...
11/22/2021
Oncology
News
RNA-sequencing Consistent With DNA-sequencing in Detecting RET fusions
10/19/2021
RNA-sequencing yields similar results to DNA-sequencing in detecting RET fusions among patients with lung adenocarcinoma.
RNA-sequencing yields similar results to DNA-sequencing in detecting RET fusions among patients with lung adenocarcinoma.
RNA-sequencing yields similar...
10/19/2021
Oncology
Conference Coverage
Pralsetinib Shows Promise in Chinese Patients with RET+ NSCLC
09/14/2021
Pralsetinib shows promise as a targeted therapy in Chinese patients with advanced RET+ NSCLC, according to data presented at the 2021 IASLC World Conference on Lung Cancer.
Pralsetinib shows promise as a targeted therapy in Chinese patients with advanced RET+ NSCLC, according to data presented at the 2021 IASLC World Conference on Lung Cancer.
Pralsetinib shows promise as a...
09/14/2021
Oncology
Test Your Knowledge
Quiz: Is Pralsetinib Beneficial for RET+ NSCLC?
08/06/2021
True or false: Oral pralsetinib has been shown to yield promising overall response rates in patients with RET+ NSCLC.
True or false: Oral pralsetinib has been shown to yield promising overall response rates in patients with RET+ NSCLC.
True or false: Oral pralsetinib...
08/06/2021
Oncology

News

News
FDA Approves Selpercatinib for Locally Advanced or Metastatic RET Fusion-Positive NSCLC and Solid Tumors
09/22/2022

Derek Cowsert

Derek Cowsert
On September 21, 2022, the FDA granted approval to oral kinase inhibitor, selpercatinib, either 120 mg or 160 mg twice daily based on body weight (less than 50 kg vs more than 50 kg, respectively), for adult patients with locally advanced or...
On September 21, 2022, the FDA granted approval to oral kinase inhibitor, selpercatinib, either 120 mg or 160 mg twice daily based on body weight (less than 50 kg vs more than 50 kg, respectively), for adult patients with locally advanced or...
On September 21, 2022, the FDA...
09/22/2022
Oncology
Conference Coverage
Experts Observe Durable Antitumor Activity With Selpercatinib for RET Fusion-Positive Solid Tumors
06/28/2022

Hina M. Porcelli

Hina M. Porcelli
Selpercatinib continues to demonstrate robust antitumor activity in patients with varying RET fusion-positive solid tumor cancers, according to an update from the LIBRETTO-001 trial presented at the 2022 ASCO Annual Meeting.
Selpercatinib continues to demonstrate robust antitumor activity in patients with varying RET fusion-positive solid tumor cancers, according to an update from the LIBRETTO-001 trial presented at the 2022 ASCO Annual Meeting.
Selpercatinib continues to...
06/28/2022
Oncology
News
Selpercatinib Demonstrates Safety, Efficacy in RET-Altered NSCLC and Thyroid Cancer Regardless of Prior Treatment Status
06/28/2022

Hina M. Porcelli

Hina M. Porcelli
Findings from a systematic review and meta-analysis show that selpercatinib is a safe and effective option for patients with RET-altered NSCLC and thyroid cancer, regardless of previous therapies or RET alteration type.
Findings from a systematic review and meta-analysis show that selpercatinib is a safe and effective option for patients with RET-altered NSCLC and thyroid cancer, regardless of previous therapies or RET alteration type.
Findings from a systematic...
06/28/2022
Oncology
News
European Commission Approves Pralsetinib for Patients with RET+ NSCLC
12/15/2021
The EC has granted conditional marketing authorization to pralsetinib for treatment-naive adult patients with RET-fusion positive NSCLC.
The EC has granted conditional marketing authorization to pralsetinib for treatment-naive adult patients with RET-fusion positive NSCLC.
The EC has granted conditional...
12/15/2021
Oncology
News
RNA-sequencing Consistent With DNA-sequencing in Detecting RET fusions
10/19/2021
RNA-sequencing yields similar results to DNA-sequencing in detecting RET fusions among patients with lung adenocarcinoma.
RNA-sequencing yields similar results to DNA-sequencing in detecting RET fusions among patients with lung adenocarcinoma.
RNA-sequencing yields similar...
10/19/2021
Oncology
Conference Coverage
Pralsetinib Shows Promise in Chinese Patients with RET+ NSCLC
09/14/2021
Pralsetinib shows promise as a targeted therapy in Chinese patients with advanced RET+ NSCLC, according to data presented at the 2021 IASLC World Conference on Lung Cancer.
Pralsetinib shows promise as a targeted therapy in Chinese patients with advanced RET+ NSCLC, according to data presented at the 2021 IASLC World Conference on Lung Cancer.
Pralsetinib shows promise as a...
09/14/2021
Oncology
News
Pralsetinib Demonstrates High Potency, Promise in Patients With RET+ NSCLC
07/19/2021
Pralsetinib shows high potency, convenient oral administration, and selective RET inhibition in patients with RET-positive NSCLC, according to data from the ARROW study.
Pralsetinib shows high potency, convenient oral administration, and selective RET inhibition in patients with RET-positive NSCLC, according to data from the ARROW study.
Pralsetinib shows high potency,...
07/19/2021
Oncology
News
Selpercatinib Superior to Prior Systemic Therapy in RET-Positive NSCLC
06/22/2021
Patients with RET-positive NSCLC who received selpercatinib therapy had a better overall response than those who received prior systemic therapy, according to findings from the phase 1/2 LIBRETTO-001 trial.
Patients with RET-positive NSCLC who received selpercatinib therapy had a better overall response than those who received prior systemic therapy, according to findings from the phase 1/2 LIBRETTO-001 trial.
Patients with RET-positive NSCLC...
06/22/2021
Oncology
News
Combination Therapy May Target MET-Dependent Resistance in RET-Positive NSCLC
04/12/2021
Study findings suggest combining selpercatinib with crizotinib may be promising in targeting MET-amplified resistance among patients with RET-positive NSCLC vs selpercatinib alone.
Study findings suggest combining selpercatinib with crizotinib may be promising in targeting MET-amplified resistance among patients with RET-positive NSCLC vs selpercatinib alone.
Study findings suggest combining...
04/12/2021
Oncology
News
Selpercatinib Safe, Effective for Medullary Thyroid Cancer With RET Mutation
01/20/2021
Selpercatinib was shown to be effective, with manageable safety, in patients with RET+ medullary thyroid cancer in a phase 1/2 trial.
Selpercatinib was shown to be effective, with manageable safety, in patients with RET+ medullary thyroid cancer in a phase 1/2 trial.
Selpercatinib was shown to be...
01/20/2021
Oncology

Interactive

Quiz
Quiz: Complete Responses With Pralsetinib in Patients With RET-Altered NSCLC on the ARROW Trial
07/25/2022
According to an interim analysis of the multi-cohort, open-label, phase 1/2 ARROW trial, how many patients with RET+ NSCLC a complete response when treated with pralsetinib?
According to an interim analysis of the multi-cohort, open-label, phase 1/2 ARROW trial, how many patients with RET+ NSCLC a complete response when treated with pralsetinib?
According to an interim analysis...
07/25/2022
Oncology
Quiz
Quiz: Selpercatinib Maintains Antitumor Activity in Which Types of RET Fusion-Positive Cancers?
07/19/2022
Findings from the phase 1/2 LIBRETTO-001 trial found that selpercatinib yielded durable antitumor activity in patients with what types of locally advanced and/or metastatic RET fusion-positive solid tumors?
Findings from the phase 1/2 LIBRETTO-001 trial found that selpercatinib yielded durable antitumor activity in patients with what types of locally advanced and/or metastatic RET fusion-positive solid tumors?
Findings from the phase 1/2...
07/19/2022
Oncology
Quiz
Quiz: Selpercatinib vs Other Non-Specific RET Inhibitors for RET-Altered NSCLC and Thyroid Cancer
07/13/2022
On indirect comparison, did study findings presented at the 2022 ASCO Annual Meeting find the safety profile with selpercatinib to be better, worse, or similar compared to previously used non-specific RET-inhibitors in patients with...
On indirect comparison, did study findings presented at the 2022 ASCO Annual Meeting find the safety profile with selpercatinib to be better, worse, or similar compared to previously used non-specific RET-inhibitors in patients with...
On indirect comparison, did...
07/13/2022
Oncology
Test Your Knowledge
Quiz: Is RNA-Sequencing Consistent In Detecting RET Fusions in Lung Adenocarcinoma?
11/22/2021
True or false: RNA-sequencing was not consistent with DNA-sequencing in detecting RET fusions.
True or false: RNA-sequencing was not consistent with DNA-sequencing in detecting RET fusions.
True or false: RNA-sequencing...
11/22/2021
Oncology
Test Your Knowledge
Quiz: Is Pralsetinib Beneficial for RET+ NSCLC?
08/06/2021
True or false: Oral pralsetinib has been shown to yield promising overall response rates in patients with RET+ NSCLC.
True or false: Oral pralsetinib has been shown to yield promising overall response rates in patients with RET+ NSCLC.
True or false: Oral pralsetinib...
08/06/2021
Oncology
Test Your Knowledge
Quiz: Combo Therapy for MET-Dependent Resitance in RET+ NSCLC
04/30/2021
True or false: Selpercatinib in combination with crizotinib targets MET-amplified resistance found in RET+ non-small cell lung cancer.
True or false: Selpercatinib in combination with crizotinib targets MET-amplified resistance found in RET+ non-small cell lung cancer.
True or false: Selpercatinib in...
04/30/2021
Oncology
Test Your Knowledge
Quiz: Which Treatment Was Recently Granted Accelerated Approval in RET-Altered Thyroid Cancers?
01/11/2021
Which of the following applications were recently granted accelerated approval by the FDA for adult and pediatric advanced or metastatic RET-altered thyroid cancer requiring systemic therapy?
Which of the following applications were recently granted accelerated approval by the FDA for adult and pediatric advanced or metastatic RET-altered thyroid cancer requiring systemic therapy?
Which of the following...
01/11/2021
Oncology
Test Your Knowledge
Quiz: Pembrolizumab Plus Docetaxel for Advanced, Pretreated NSCLC
04/29/2020
True or False: In a phase 2 clinical trial, pembrolizumab plus docetaxel did not improve overall response rates and progression-free survival in pretreated patients with NSCLC.
True or False: In a phase 2 clinical trial, pembrolizumab plus docetaxel did not improve overall response rates and progression-free survival in pretreated patients with NSCLC.
True or False: In a phase 2...
04/29/2020
Oncology

Advertisement

Advertisement

Advertisement

Advertisement

Recent News

News
FDA Approves Selpercatinib for Locally Advanced or Metastatic RET Fusion-Positive NSCLC and Solid Tumors
09/22/2022

Derek Cowsert

Derek Cowsert
On September 21, 2022, the FDA granted approval to oral kinase inhibitor, selpercatinib, either 120 mg or 160 mg twice daily based on body weight (less than 50 kg vs more than 50 kg, respectively), for adult patients with locally advanced or...
On September 21, 2022, the FDA granted approval to oral kinase inhibitor, selpercatinib, either 120 mg or 160 mg twice daily based on body weight (less than 50 kg vs more than 50 kg, respectively), for adult patients with locally advanced or...
On September 21, 2022, the FDA...
09/22/2022
Oncology
Conference Coverage
Experts Observe Durable Antitumor Activity With Selpercatinib for RET Fusion-Positive Solid Tumors
06/28/2022

Hina M. Porcelli

Hina M. Porcelli
Selpercatinib continues to demonstrate robust antitumor activity in patients with varying RET fusion-positive solid tumor cancers, according to an update from the LIBRETTO-001 trial presented at the 2022 ASCO Annual Meeting.
Selpercatinib continues to demonstrate robust antitumor activity in patients with varying RET fusion-positive solid tumor cancers, according to an update from the LIBRETTO-001 trial presented at the 2022 ASCO Annual Meeting.
Selpercatinib continues to...
06/28/2022
Oncology
News
Selpercatinib Demonstrates Safety, Efficacy in RET-Altered NSCLC and Thyroid Cancer Regardless of Prior Treatment Status
06/28/2022

Hina M. Porcelli

Hina M. Porcelli
Findings from a systematic review and meta-analysis show that selpercatinib is a safe and effective option for patients with RET-altered NSCLC and thyroid cancer, regardless of previous therapies or RET alteration type.
Findings from a systematic review and meta-analysis show that selpercatinib is a safe and effective option for patients with RET-altered NSCLC and thyroid cancer, regardless of previous therapies or RET alteration type.
Findings from a systematic...
06/28/2022
Oncology
News
European Commission Approves Pralsetinib for Patients with RET+ NSCLC
12/15/2021
The EC has granted conditional marketing authorization to pralsetinib for treatment-naive adult patients with RET-fusion positive NSCLC.
The EC has granted conditional marketing authorization to pralsetinib for treatment-naive adult patients with RET-fusion positive NSCLC.
The EC has granted conditional...
12/15/2021
Oncology
News
RNA-sequencing Consistent With DNA-sequencing in Detecting RET fusions
10/19/2021
RNA-sequencing yields similar results to DNA-sequencing in detecting RET fusions among patients with lung adenocarcinoma.
RNA-sequencing yields similar results to DNA-sequencing in detecting RET fusions among patients with lung adenocarcinoma.
RNA-sequencing yields similar...
10/19/2021
Oncology
News
Pralsetinib Demonstrates High Potency, Promise in Patients With RET+ NSCLC
07/19/2021
Pralsetinib shows high potency, convenient oral administration, and selective RET inhibition in patients with RET-positive NSCLC, according to data from the ARROW study.
Pralsetinib shows high potency, convenient oral administration, and selective RET inhibition in patients with RET-positive NSCLC, according to data from the ARROW study.
Pralsetinib shows high potency,...
07/19/2021
Oncology
News
Selpercatinib Superior to Prior Systemic Therapy in RET-Positive NSCLC
06/22/2021
Patients with RET-positive NSCLC who received selpercatinib therapy had a better overall response than those who received prior systemic therapy, according to findings from the phase 1/2 LIBRETTO-001 trial.
Patients with RET-positive NSCLC who received selpercatinib therapy had a better overall response than those who received prior systemic therapy, according to findings from the phase 1/2 LIBRETTO-001 trial.
Patients with RET-positive NSCLC...
06/22/2021
Oncology
News
Combination Therapy May Target MET-Dependent Resistance in RET-Positive NSCLC
04/12/2021
Study findings suggest combining selpercatinib with crizotinib may be promising in targeting MET-amplified resistance among patients with RET-positive NSCLC vs selpercatinib alone.
Study findings suggest combining selpercatinib with crizotinib may be promising in targeting MET-amplified resistance among patients with RET-positive NSCLC vs selpercatinib alone.
Study findings suggest combining...
04/12/2021
Oncology
News
Selpercatinib Safe, Effective for Medullary Thyroid Cancer With RET Mutation
01/20/2021
Selpercatinib was shown to be effective, with manageable safety, in patients with RET+ medullary thyroid cancer in a phase 1/2 trial.
Selpercatinib was shown to be effective, with manageable safety, in patients with RET+ medullary thyroid cancer in a phase 1/2 trial.
Selpercatinib was shown to be...
01/20/2021
Oncology
News
FDA Approves Pralsetinib for RET-Altered Thyroid Cancers
12/02/2020
The FDA has approved pralsetinib for the treatment of adult and pediatric patients with RET-mutated thyroid cancer.
The FDA has approved pralsetinib for the treatment of adult and pediatric patients with RET-mutated thyroid cancer.
The FDA has approved pralsetinib...
12/02/2020
Oncology
News
Cabozantinib Shows Promising Activity Among Patients With Progressive, Unresectable Metastatic Phaeochromocytomas and Paragangliomas
04/25/2024

Stephanie Holland 

Stephanie Holland 
According to results from the phase 2 Natalie trial, cabozantinib showed promising clinical activity among patients with progressive, unresectable metastatic phaeochromocytomas and paragangliomas.
According to results from the phase 2 Natalie trial, cabozantinib showed promising clinical activity among patients with progressive, unresectable metastatic phaeochromocytomas and paragangliomas.
According to results from the...
04/25/2024
Oncology
News
Adjuvant Pembrolizumab Significantly Improved Overall Survival Among Patients With Clear-Cell Renal Cell Carcinoma at Increased Risk of Recurrence
04/25/2024

Stephanie Holland 

Stephanie Holland 
According to interim analysis results from the phase 3 KEYNOTE-564 trial, adjuvant pembrolizumab significantly improved overall survival compared to placebo among patients with clear-cell renal cell carcinoma at increased risk of recurrence...
According to interim analysis results from the phase 3 KEYNOTE-564 trial, adjuvant pembrolizumab significantly improved overall survival compared to placebo among patients with clear-cell renal cell carcinoma at increased risk of recurrence...
According to interim analysis...
04/25/2024
Oncology
News
FDA Grants Accelerated Approval to Tovorafenib for Patients With Relapsed or Refractory BRAF-Altered Pediatric Low-Grade Glioma
04/25/2024

Stephanie Holland 

Stephanie Holland 
Based on results from the FIREFLY-1 trial, the FDA has granted accelerated approval to tovorafenib for patients aged 6 months and older with relapsed or refractory pediatric low-grade glioma harboring a BRAF fusion, rearrangement, or a BRAF...
Based on results from the FIREFLY-1 trial, the FDA has granted accelerated approval to tovorafenib for patients aged 6 months and older with relapsed or refractory pediatric low-grade glioma harboring a BRAF fusion, rearrangement, or a BRAF...
Based on results from the...
04/25/2024
Oncology
News
Lutetium Lu 177 Dotatate Gains FDA Approval for Pediatric Patients With SSTR-Positive Gastroenteropancreatic Neuroendocrine Tumors
04/24/2024

Stephanie Holland 

Stephanie Holland 
Based on results from the NETTER-P and NETTER-1 studies, the FDA has approved lutetium Lu 177 dotatate for pediatric patients aged 12 and older with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors.
Based on results from the NETTER-P and NETTER-1 studies, the FDA has approved lutetium Lu 177 dotatate for pediatric patients aged 12 and older with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors.
Based on results from the...
04/24/2024
Oncology
News
Gemcitabine Plus Cisplatin and Intensity-Modulated Radiation Therapy Improved Response Rate Among Patients With Unresectable Vulvar Squamous Cell Carcinoma
04/23/2024

Stephanie Holland 

Stephanie Holland 
Results from the phase 2 NRG Oncology/GOG Study 279 found that gemcitabine plus cisplatin concurrently administered with intensity-modulated radiation therapy improved complete pathologic response among patients with locally advanced,...
Results from the phase 2 NRG Oncology/GOG Study 279 found that gemcitabine plus cisplatin concurrently administered with intensity-modulated radiation therapy improved complete pathologic response among patients with locally advanced,...
Results from the phase 2 NRG...
04/23/2024
Oncology
News
FDA Approves Nogapendekin Alfa Inbakicept for Patients With Bacillus Calmette-Guérin-Unresponsive Non-Muscle Invasive Bladder Cancer
04/23/2024

Stephanie Holland 

Stephanie Holland 
Based on results from the phase 3 QUILT-3.032 trial, the FDA has approved nogapendekin alfa inbakicept for patients with Bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer.
Based on results from the phase 3 QUILT-3.032 trial, the FDA has approved nogapendekin alfa inbakicept for patients with Bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer.
Based on results from the phase...
04/23/2024
Oncology
News
FDA Approves Adjuvant Alectinib for Patients With Resected ALK-Positive Non-Small Cell Lung Cancer
04/19/2024

Stephanie Holland 

Stephanie Holland 
Based on results from the phase 3 ALINA trial, the FDA has approved alectinib in the adjuvant setting for patients with resected ALK-positive non-small cell lung cancer.
Based on results from the phase 3 ALINA trial, the FDA has approved alectinib in the adjuvant setting for patients with resected ALK-positive non-small cell lung cancer.
Based on results from the phase...
04/19/2024
Oncology
News
IV High-Dose Methotrexate With IT Liposomal Cytarabine and R-CHOP Effective for Patients With Risk of CNS Relapse, Including DLBCL With Primary Testis Localization
04/19/2024

Amber Denham

Amber Denham
According to phase 2 results, intravenous high-dose methotrexate in combination with intrathecal liposomal cytarabine and R-CHOP is effective among patient populations with high risk of central nervous system relapse, specifically those with...
According to phase 2 results, intravenous high-dose methotrexate in combination with intrathecal liposomal cytarabine and R-CHOP is effective among patient populations with high risk of central nervous system relapse, specifically those with...
According to phase 2 results,...
04/19/2024
Oncology
News
Elranatamab vs Teclistamab Treatment Among Patients With Triple-Class Exposed/Refractory Multiple Myeloma
04/19/2024

Jordan Kadish 

Jordan Kadish 
According to findings from an unanchored matching-adjusted indirect comparison, elranatamab exhibited significantly better response and survival outcomes among patients with triple-class exposed/refractory multiple myeloma, compared with...
According to findings from an unanchored matching-adjusted indirect comparison, elranatamab exhibited significantly better response and survival outcomes among patients with triple-class exposed/refractory multiple myeloma, compared with...
According to findings from an...
04/19/2024
Oncology
News
Venetoclax Monotherapy Demonstrates Deep, Durable Responses Among Adult Patients With R/R CLL
04/18/2024

Amber Denham

Amber Denham
According to phase 3b results from the VENICE-1 trial, venetoclax monotherapy demonstrates durable responses in adult patients with relapsed/refractory chronic lymphocytic leukemia, including BCRi-pretreated patients.
According to phase 3b results from the VENICE-1 trial, venetoclax monotherapy demonstrates durable responses in adult patients with relapsed/refractory chronic lymphocytic leukemia, including BCRi-pretreated patients.
According to phase 3b results...
04/18/2024
Oncology

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Privacy Policy Terms of Use

Advertisement

Advertisement